The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?

There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a “one size fits all” approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evaluate current and potential therapies, both single-agents and combination therapies, to analyze toxicology, optimal dose, resistance, sensitivity, and biological mechanisms. It can also provide biological insight on tumor subtypes and their different responses to drugs, and indicate which patients are most likely to experience off-target effects and predict characteristics for treatment efficacy. Identifying pre-treatment metabolic profiles that correlate to these events could significantly improve how we view and treat tumors. We also briefly discuss several targeted cancer drugs that have been studied by metabolomics. We conclude that NMR technology provides a key platform in metabolomics that is well-positioned to play a crucial role in realizing the ultimate goal of better tailored cancer medicine.

[1]  Daniel Morvan,et al.  Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics. , 2010, Biochemical pharmacology.

[2]  R. Powers,et al.  Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. , 2012, ACS chemical biology.

[3]  Hans J. Vogel,et al.  Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals , 2012, Journal of proteome research.

[4]  Reino Laatikainen,et al.  High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. , 2009, The Analyst.

[5]  T. Hankemeier,et al.  Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives , 2010, Metabolomics.

[6]  S. Clarke,et al.  Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine , 2011, Clinical Cancer Research.

[7]  Mark R Viant,et al.  Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. , 2008, Analytical biochemistry.

[8]  V. Valderrábano,et al.  Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. , 2012, Clinical and experimental rheumatology.

[9]  T. Bathen,et al.  Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas , 2007, BMC Cancer.

[10]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.

[11]  D. Raftery,et al.  Metabolomics-based methods for early disease diagnostics , 2008, Expert review of molecular diagnostics.

[12]  H. Vogel,et al.  Serum metabolomic profile as a means to distinguish stage of colorectal cancer , 2012, Genome Medicine.

[13]  P. Schlag,et al.  Locoregional administration of 5-fluoro-2′-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by19F-NMR spectroscopy , 2005, Journal of Cancer Research and Clinical Oncology.

[14]  Mika Ala-Korpela,et al.  1H NMR spectroscopy of human blood plasma , 1995 .

[15]  D. Thomas,et al.  Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. , 1997, Cancer research.

[16]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[17]  Mark R. Viant,et al.  Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines , 2009, PloS one.

[18]  G. Wagner,et al.  NMR spectroscopy: a multifaceted approach to macromolecular structure , 2000, Quarterly Reviews of Biophysics.

[19]  Tanja Fehm,et al.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.

[20]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[21]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[22]  Daniel Morvan,et al.  Quantitative two‐dimensional HRMAS 1H‐NMR spectroscopy‐based metabolite profiling of human cancer cell lines and response to chemotherapy , 2010, Magnetic resonance in medicine.

[23]  M. Sawyer,et al.  Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers , 2010, Clinical Cancer Research.

[24]  L. Kay,et al.  Nuclear magnetic resonance spectroscopy of high-molecular-weight proteins. , 2004, Annual review of biochemistry.

[25]  T. Sørlie,et al.  Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts , 2013, Molecular oncology.

[26]  Elaine Holmes,et al.  The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. , 2005, Pharmacogenomics.

[27]  J. Lindon,et al.  NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. , 2008, Chemical research in toxicology.

[28]  W. Hull,et al.  Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. , 2005, Carbohydrate research.

[29]  Xian-Zhong Yan,et al.  Study of a novel indolin-2-ketone compound Z24 induced hepatotoxicity by NMR-spectroscopy-based metabonomics of rat urine, blood plasma, and liver extracts. , 2006, Toxicology and applied pharmacology.

[30]  Jan J. Heimans,et al.  Neurotoxic Complications of Chemotherapy in Patients with Cancer , 2012, Drugs.

[31]  Gary H Lyman,et al.  Impact of chemotherapy dose intensity on cancer patient outcomes. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  E. Bennett,et al.  Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. , 2007, Acta histochemica.

[33]  Henrik Antti,et al.  Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues. , 2003, Analytical biochemistry.

[34]  U. Hofmann,et al.  Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis , 2011, PloS one.

[35]  I. Sheyhidin,et al.  Revealing the metabonomic variation of EC using 1H-NMR spectroscopy and its association with the clinicopathological characteristics , 2012, Molecular Biology Reports.

[36]  Jon Brumbaugh,et al.  DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION , 2000 .

[37]  Xi-jun Wang,et al.  Urine metabolomics. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[38]  T. Veenstra,et al.  The depletion of protein signals in metabonomics analysis with the WET-CPMG pulse sequence. , 2003, Biochemical and biophysical research communications.

[39]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[40]  Ivano Bertini,et al.  Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. , 2012, Cancer research.

[41]  Timothy M. D. Ebbels,et al.  Genetic algorithms for simultaneous variable and sample selection in metabonomics , 2009, Bioinform..

[42]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[43]  D. Vriens,et al.  Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. , 2011, Clinical colorectal cancer.

[44]  F. Blankenberg,et al.  Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. , 1997, Blood.

[45]  T. Bathen,et al.  Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. , 2010, Cancer research.

[46]  Daniel Monleón,et al.  Metabolite profiling of fecal water extracts from human colorectal cancer , 2009, NMR in biomedicine.

[47]  Daniel Morvan,et al.  Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses , 2010, Breast Cancer Research and Treatment.

[48]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[49]  Elaine Holmes,et al.  Evaluation of full-resolution J-resolved 1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification. , 2010, Analytical chemistry.

[50]  T. Bathen,et al.  HR MAS MR spectroscopy in metabolic characterization of cancer. , 2011, Current topics in medicinal chemistry.

[51]  Richard D. Beger,et al.  NMR-based metabonomic evaluation of livers from rats chronically treated with tamoxifen, mestranol, and phenobarbital , 2005, Metabolomics.

[52]  Royston Goodacre,et al.  Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. , 2011, Chemical Society reviews.

[53]  Paul D. Martin,et al.  Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. , 2012, Clinical therapeutics.

[54]  Feng Han,et al.  Tumor and Stem Cell Biology Cancer Research GlcNAcylation Plays an Essential Role in Breast Cancer Metastasis , 2010 .

[55]  D. Wishart,et al.  The human cerebrospinal fluid metabolome. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[56]  M. Viant.  Improved methods for the acquisition and interpretation of NMR metabolomic data. , 2003, Biochemical and biophysical research communications.

[57]  P. Kountourakis,et al.  Targeting the HER2 receptor in metastatic breast cancer. , 2012, Hematology/oncology and stem cell therapy.

[58]  C. Milikowski,et al.  A case report - Volatile metabolomic signature of malignant melanoma using matching skin as a control. , 2011, Journal of cancer science & therapy.

[59]  Mark R Viant,et al.  Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. , 2010, Phytochemical analysis : PCA.

[60]  M. Kersten,et al.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  E. Fukusaki,et al.  Current metabolomics: practical applications. , 2013, Journal of bioscience and bioengineering.

[62]  G. Morgan,et al.  Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease , 2013, PloS one.

[63]  P. Hajduk,et al.  NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.

[64]  Erin E. Carlson,et al.  Targeted profiling: quantitative analysis of 1H NMR metabolomics data. , 2006, Analytical chemistry.

[65]  V. Appanna,et al.  The Tricarboxylic Acid Cycle, an Ancient Metabolic Network with a Novel Twist , 2007, PloS one.

[66]  Theodoros N. Arvanitis,et al.  In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. , 2011, Journal of proteome research.

[67]  Stefano Tiziani,et al.  Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. , 2009, Neoplasia.

[68]  Ping Zang,et al.  1H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system , 2011, Journal of biomolecular NMR.

[69]  Oliver F Bathe,et al.  Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[70]  N. Serkova,et al.  Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. , 2011, Anticancer research.

[71]  M. Arbushites,et al.  Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study , 2012, Molecular oncology.

[72]  K. Suhre,et al.  Metabolomics platforms for genome wide association studies--linking the genome to the metabolome. , 2013, Current opinion in biotechnology.

[73]  A deserving role for the National Center for Advancing Translational Sciences , 2011, The Lancet.

[74]  John C Lindon,et al.  The comparison of plasma deproteinization methods for the detection of low-molecular-weight metabolites by (1)H nuclear magnetic resonance spectroscopy. , 2002, Analytical biochemistry.

[75]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[76]  N. Bouchemal,et al.  Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells , 2010, NMR in biomedicine.

[77]  H. Keun,et al.  Metabolic signatures of malignant progression in prostate epithelial cells. , 2011, The international journal of biochemistry & cell biology.

[78]  Hanne Christine Bertram,et al.  Potential of human saliva for nuclear magnetic resonance-based metabolomics and for health-related biomarker identification. , 2009, Analytical chemistry.

[79]  D. Spandidos,et al.  Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). , 2011, Molecular medicine reports.

[80]  M. Spraul,et al.  750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.

[81]  D. Solís.  US Food and Drug Administration , 2010 .

[82]  F. Moussallieh,et al.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy , 2011, Journal of oncology.

[83]  W. Xue,et al.  NMR-based Metabolomic Analysis of Human Bladder Cancer , 2012, Analytical Sciences.

[84]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[85]  Ad Bax,et al.  Weak alignment NMR: a hawk-eyed view of biomolecular structure. , 2005, Current opinion in structural biology.

[86]  Jeffrey M. Macdonald,et al.  Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by 1H NMR spectroscopy , 2010, Metabolomics.

[87]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  S. Hirschfeld,et al.  Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. , 2001, The oncologist.

[89]  Aihua Zhang,et al.  Metabolomics: towards understanding traditional Chinese medicine. , 2010, Planta medica.

[90]  T. Sugiyama,et al.  Long-Term Follow-Up Outcome of Imatinib Mesylate Treatment for Recurrent and Unresectable Gastrointestinal Stromal Tumors , 2013, Digestion.

[91]  Vitor Sousa,et al.  Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. , 2011, Journal of proteome research.

[92]  Fabian J Theis,et al.  Body Fat Free Mass Is Associated with the Serum Metabolite Profile in a Population-Based Study , 2012, PloS one.

[93]  Sham S. Kakar,et al.  Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer , 2011, PloS one.

[94]  H. Vogel,et al.  An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. , 2007, Journal of proteome research.